Contact: [email protected]
* Studie on hold of geen beschikbare plaatsen
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| Regina | Rectal | Neoadjuvant | Regorafenib + nivolumab + short course RT in intermediate risk stage II-III |
| AZUR-2 | CRC | Neoadjuvant | Rand. study of perioperative Dostarlimab mono vs. SOC (surgery + adj chemo) in T4N0 or Stage III dMMR/MSI-H resectable CRC |
| IMCODE003 (GO44479)* | Pancreas | Adjuvant | Autogen cevumeran IV + atezo + mFOLFIRINOX vs. mFOLFIRINOX; screening before surgery |
| Nalpac | Pancreas | 2L | Naliri vs Nalirinox. PD after 1st line gemcitabine mono or gem/abraxane |
| Stereopac | Pancreas | Neoadjuvant | preop mFOLFIRINOX (or gem/NabP) +/- SBRT in borderline resectable |
| Mountaineer-03 (SGNTUC-029) | CRC | 1L | Tucatinib+trastuzumab + mFOLFOX6 vs. mFOLFOX6 +/- bevacizumab/cetuximab in HER2+, RAS wt CRC |
| Imbrave152 | HCC | 1L | Tiragolumab (anit-TIGIT) vs. placebo + atezolizumab + bevacizumab |
| REPLACE (TRIO 041) | HCC | 1L | Regorafenib + pembrolizumab vs. TACE or TARE |
| TT420C2308 (FIRST-308)* | Cholangio | >1L | Tinengotinib (PO) vs. Physician’s choice therapy; prior FGFR inhibitor required |
| BI1438-0007 (DAREON-7) | NEC | 1L | BI764532 + etoposide + platinum in DLL3+ (phase 1) |
| IL15 TransDC | Pancreas | >1L | IL15 TransDC vaccin (6 vaccinations, concomitant anti-cancer therapy possible 7D after V2; phase 1) |